The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

Mon, 14th Jun 2021 13:19

(Alliance News) - The following is a round-up of updates by London-listed companies issued on Monday and not separately reported by Alliance News:

----------

Synectics PLC - Sheffield, England-based security systems services company - Says trading in the six months to the end of May continued at similar levels as last year, with estimated operating loss of GBP800,000 versus GBP2.0 million in the first half of the prior financial year. This follows action taken last year to reduce Synectics' operating cost base. Revenue declined 4.3% to GBP22 million from GBP23 million year-on-year.

----------

Inspirit Energy Holdings PLC - London-based heat and power appliances manufacturer - Says it has been working with its engineering partners on the details of the new waste heat recovery systems for the application on the Volvo marine engine. Details of the electrical and the main mechanical systems are near completion, Inspirit says. It expects that by the end of 2021, all major items of the waste heat recovery system will be complete, with a view to having the designs for a full working prototype that can be put into manufacture. Inspirit is working with marine engine maker Volvo Penta.

----------

Active Energy Group PLC - London-based renewable energy company - Reports USD9.0 million of pretax loss from continuing operations in 2020, widened from USD3.3 million the year before. This is the result of USD4.8 million of impairment charges recorded in 2020 versus no such charges the year earlier. They relate to the impairment of non-core assets and the decision to focus resources on commercialisation of CoalSwitch. Revenue slips 5.2% to USD1.8 million from USD1.9 million.

----------

Scirocco Energy PLC - seeking investments in production and development opportunities within the European energy market - Reports widened pretax loss of GBP3.3 million for 2020 compared to GBP2.6 million the year before, amid higher administrative expenses. Has no revenue in either year. Scirocco notes continued focus on cost discipline, including salary sacrifices and implementation of option based remuneration for executives. Also proposes investment in Energy Acquisitions Group Ltd, a specialist acquisition and operating vehicle in the sustainable energy sector. The investment in conditional on shareholder approval for a change in the company's investing policy. This investment of GBP1.2 million will be funded from current cash resources. EAG will use the funds to buy Greenan Generation Ltd, which has an anaerobic digestion renewable energy plant in Northern Ireland.

----------

Helium One Ltd - helium exploration and development company - Says three well exploration programme targeting shallow trap structures to a maximum depth of 1,200 metres has started at Rukwa project. Each well will take about one month to complete. "We look forward to announcing results of our first well at what is a potentially transformative time for the company," says CEO David Minchin. Scirocco Energy notes the update by Helium One, in which it has 1.2% holding.

----------

Nostra Terra Oil & Gas Co PLC - oil & gas exploration and production company focussed on the US state of Texas - Reports revenue for 2020 of USD1.0 million, down from USD1.8 million recorded in 2019. Production for the year was 29,583 barrels of oil, lower than 33,179 barrels of oil in 2019. Despite that, pretax loss narrowed to USD1.3 million from USD1.7 million year-on-year, as administrative expenses were reduced to USD896,000 from USD1.6 million. "2020 was a very challenging year for businesses around the world, with oil & gas companies amongst the worst hit," notes Chief Executive Matt Lofgran.

----------

Distil PLC - London-based owner of premium drinks brands - Says turnover in 2020 increased 48% to GBP3.6 million from GBP2.4 million, as it increased export sales of existing brands by 81% year-on-year. Advertising & promotion spend increased 61% to GBP1.1 million from GBP665,000 the year prior and other administrative expenses increased 9% to GBP651,000 from GBP597,000 year-on-year. Despite the increased spending, pretax profit rose to GBP243,000 from GBP182,000.

----------

Tanfield Group PLC - UK-based investment firm - Reports pretax loss from operations of GBP697,000 for 2020, widened from GBP317,000 posted the year before, due to higher interest costs and an increase in legal fees due to ongoing US and UK court proceedings. Tanfield's 51% joint venture partner Xtreme Manufacturing LLC, via its subsidiary SKL Holdings LLC and Snorkel International, filed a summons and complaint against Tanfield and its subsidiary HBWP Inc. Tanfield said it remains "disappointed" that a resolution has not been possible and therefore continues to seek advice and defend its position.

----------

Thalassa Holdings Ltd - invests in real estate, fintech and robotics - Reports swing to pretax profit of USD1.6 million in 2020 from loss of USD3.8 million, despite revenue falling to USD55,855 from USD170,357. The swing to pretax profit comes amid reduction in administrative expenses to USD3.2 million from USD4.2 million year-on-year and the booking of finance income of USD3.6 million versus finance expense of USD640,117 the year before.

----------

SourceBio International PLC - Nottingham, England-based provider of laboratory services - Continues to trade well since the end of 2020 with revenue, earnings and cash generation in the year-to-date significantly ahead of the equivalent period last year. Going forward, expects peak levels of revenue and earnings to be generated from anticipated high levels of travel-related virus testing in the coming months. SourceBio says it remains optimistic for the remainder of the year and beyond as a result.

----------

Evgen Pharma PLC - Liverpool-based clinical stage drug development company - Reports clinical trial plans for SFX-01 in glioblastoma. Glioma is the most common form of brain tumour. Previously the company reported that data generated by University L'Aquila showed that with pre-clinical subcutaneous and orthotopic models, SFX-01 produced tumour shrinkage and significantly extended survival times. Evgen now reports that data from these experiments have been reproduced with very similar results at the University of Auckland using cells generated from freshly extracted patient glioblastoma tissue, rather than the standard glioblastoma cell lines established many decades previously. Going forward, Evgen says plans for a phase II glioblastoma clinical trial with an adaptive design are progressing with a scheduled start in the first half of 2022.

Separately, Evgen reports new preclinical data which shows SFX-01 may be of benefit to metastatic breast cancer patients who have become resistant to CDK4/6 inhibitors. Should these results be reinforced, Evgen will pursue a phase II placebo-controlled study a in second-line estrogen receptor positive metastatic breast cancer treatment of patients who have failed on CDK4/6 inhibitors. Such a trial could commence in 2022.

----------

nmcn PLC - Nottinghamshire-based construction engineering company - Says it is now in bilateral discussions with a party to conclude a refinancing. The company says it is working towards reaching a position where the refinancing will be announced within the next week enabling nmcn to address its current significant working capital strain. Should the refinancing not be successfully concluded the group will have to consider its remaining options.

----------

Apollon Formularies PLC - London-based medical cannabis company - Says Apollon Formularies Jamaica has signed a long-term lease for its first International Cancer Institute in the Jamaican capital of Kingston. The new facility will specialise in complementary and alternative medical treatments for cancer patients. These treatments will include Apollon's medical cannabis products.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
2 Aug 2023 10:09

AIM WINNERS & LOSERS: Deltex plummets on return to AIM; Blancco rises

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
13 Jul 2023 15:58

UK shareholder meetings calendar - next 7 days

Friday 14 July 
Templeton Emerging Markets Investment Trust PLCAGM
Monday 17 July 
All ThingsConsidered Group PLCAGM
Tower Resources PLCAGM
Tuesday 18 July 
Alkemy Capital Investments PLCAGM
Bloomsbury Publishing PLCAGM
CT Property Trust LtdGM re takeover by LondonMetric Property
e-Therapeutics PLCAGM
MobilityOne LtdEGM re Tete planned JV deadline extension
SmartSpace Software PLCAGM
Strategic Minerals PLCAGM
Wynnstay Properties PLCAGM
Wednesday 19 July 
Berkeley Energia LtdAGM
Caledonian Trust PLCAGM
DG Innovate PLCAGM
Experian PLCAGM
HICL Infrastructure PLCAGM
Mind Gym PLCAGM
Sportech PLCGM re share capital restructure
Triple Point Income VCT PLCAGM
Thursday 20 July 
ACG Acquisition Co LtdEGM re acquisition of the Atlantic Nickel
Big Yellow Group PLCAGM
CT UK High Income Trust PLCAGM
Evgen Pharma PLCAGM
FD Technologies PLCAGM
Fuller, Smith & Turner PLCAGM
GB Group PLCAGM
Halma PLCAGM
Intermediate Capital Group PLCAGM
International Distributions Services PLCAGM
Fidelity China Special Situations PLCAGM
Johnson Matthey PLCAGM
Kingspan Group PLCEGM re delisting
Pennon Group PLCAGM
Premier Foods PLCAGM
Premier Miton Group PLCAGM
Qinetiq Group PLCAGM
SSE PLCAGM
TR Property Investment Trust PLCAGM
VP PLCAGM
Weiss Korea Opportunity Fund LtdAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
27 Jun 2023 10:17

AIM WINNERS & LOSERS: Unbound shares drop as calls off sales process

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
27 Jun 2023 10:01

Evgen Pharma's SFX-01 has positive effects for treating a rare cancer

(Alliance News) - Evgen Pharma PLC on Tuesday said its lead asset SFX-01 has radio-sensitising effects in vivo in a form of soft tissue sarcoma, as part of its research partnership with Sapienza University of Rome.

Read more
19 Jun 2023 10:05

Evgen collaborator receives grant from KWF Dutch Cancer Society

(Alliance News) - Evgen Pharma PLC on Monday said its collaborator at the Erasmus University Medical Center in Rotterdam has received notice of a grant from KWF Dutch Cancer Society.

Read more
7 Jun 2023 11:41

Evgen Pharma confident amid Stalicla deal; CFO Moulson to retire

(Alliance News) - Evgen Pharma PLC on Wednesday reported a widened annual loss and said its Chief Financial Officer Richard Moulson will retire in late July.

Read more
31 May 2023 15:46

UK earnings, trading statements calendar - next 7 days

Thursday 1 June 
Auto Trader Group PLCFull Year Results
Dr Martens PLCFull Year Results
Pennon Group PLCFull Year Results
Trinity Exploration & Production PLCFull Year Results
Friday 2 June 
TR Property Investment Trust PLCFull Year Results
Nostrum Oil & Gas PLCFull Year Results
Monday 5 June 
Celadon Pharmaceuticals PLCFull Year Results
Hercules Site Services PLCHalf Year Results
Itaconix PLCFull Year Results
Sirius Real Estate LtdFull Year Results
ValiRx PLCFull Year Results
Verici Dx PLCFull Year Results
Tuesday 6 June 
British American Tobacco PLCTrading Statement
Chemring Group PLCHalf Year Results
Ferguson PLCQ3 Results
Gooch & Housego PLCHalf Year Results
Jadestone Energy PLCFull Year Results
N Brown Group PLCFull Year Results
NewRiver REIT PLCFull Year Results
Oxford Metrics PLCHalf Year Results
Paragon Banking Group PLCHalf Year Results
Speedy Hire PLCFull Year Results
Warehouse REIT PLCFull Year Results
Wednesday 7 June 
discoverIE Group PLCFull Year Results
Evgen Pharma PLCFull Year Results
LXi REIT PLCFull Year Results
Ramsdens Holdings PLCHalf Year Results
Residential Secure Income PLCHalf Year Results
Vp PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
22 Mar 2023 11:10

IN BRIEF: Evgen Pharma shares up as pharmacokinetic data announced

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focusing on sulforaphane-based medicines - Presents top line pharmacokinetic data for its placebo-controlled, dose-escalating, randomised Phase I/Ib clinical trial. Says the study is aimed to provide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric coated tablet formulation of the company's lead asset SFX-01, as well as investigating how sulforaphane released from the tablet engages with targets of interest. Says SFX-01 shows no serious adverse effects and the study is on schedule for full reporting in the second quarter.

Read more
22 Mar 2023 10:30

AIM WINNERS & LOSERS: Pathfinder finds way forward in Mozambique

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
16 Mar 2023 16:35

Evgen notes evidence of radiosensitisation by SFX-01 in cancer cells

(Alliance News) - Evgen Pharma PLC said on Thursday it had found further evidence of radiosensitisation by SFX-01 in sarcoma cells.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
25 Jan 2023 10:40

Evgen Pharma completes dosing of clinical trial for SFX-01 tablet

(Alliance News) - Evgen Pharma PLC on Wednesday said it completed the dosing of all three cohorts of the phase 1/1b clinical trial of its SFX-01 tablet formulation.

Read more
8 Dec 2022 13:57

Evgen Pharma loss, operating expenses widen; SFX-01 study on schedule

(Alliance News) - Evgen Pharma PLC on Thursday said interim loss widened, but noted the healthy volunteer study of its SFX-01 formulation remains on schedule.

Read more
16 Nov 2022 16:11

Evgen Pharma starts clinical trial of new SFX-01 tablet

(Alliance News) - Evgen Pharma PLC said on Wednesday it had started a randomised, placebo-controlled clinical trial of its new SFX-01 tablet.

Read more
16 Nov 2022 14:05

Evgen Pharma doses first volunteers in SFX-01 trial

(Sharecast News) - Clinical-stage drug developer Evgen Pharma has dosed the first group of healthy volunteers in its placebo-controlled, dose-escalating, randomised phase 1 and 1b clinical trial, it announced on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.